

## Medical Coverage Policy | Scintimammography and Gamma Imaging of the Breast and Axilla



**EFFECTIVE DATE:** 01|01|2019

**POLICY LAST UPDATED:** 08|16|2023

### OVERVIEW

Scintimammography refers to the use of radiotracers with nuclear medicine imaging as a diagnostic tool for abnormalities of the breast. Breast-Specific Gamma Imaging (BSGI), or Molecular Breast Imaging (MBI), refers to specific types of imaging machines that are used in conjunction with scintimammography to improve diagnostic performance.

This policy is applicable only for Scintimammography. For use of gamma detection following radiopharmaceutical administration for localization of sentinel lymph nodes in patients with breast cancer please refer to the High-Tech Radiology policy.

### MEDICAL CRITERIA

Not applicable

### PRIOR AUTHORIZATION

Not applicable

### POLICY STATEMENT

#### Medicare Advantage Plans

Scintimammography, Breast-Specific Gamma Imaging, and Molecular Breast Imaging are considered not covered in all applications, including but not limited to their use as an adjunct to mammography or in staging the axillary lymph nodes as the evidence is insufficient to determine the effects of the technology on health outcomes.

#### Commercial Products

Scintimammography, Breast-Specific Gamma Imaging, and Molecular Breast Imaging are considered not medically necessary in all applications, including but not limited to their use as an adjunct to mammography or in staging the axillary lymph nodes as the evidence is insufficient to determine the effects of the technology on health outcomes.

### COVERAGE

#### Medicare Advantage Plans and Commercial Products

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

### BACKGROUND:

Scintimammography is a diagnostic modality using radiopharmaceuticals to detect tumors of the breast. After injection of a radiopharmaceutical, the breast is evaluated with planar imaging. Scintimammography is performed with the patient lying prone and the camera positioned laterally, which increases the distance between the breast and the camera. Scintimammography using conventional imaging modalities has relatively poor sensitivity in detecting smaller lesions (e.g., smaller than 15 mm), because of the relatively poor resolution of conventional gamma cameras in imaging the breast.

BSGI and MBI were developed to address this issue. Breast-specific gamma cameras acquire images while the patient is seated in a position similar to that in mammography, and the breast is lightly compressed. The detector head(s) is immediately next to the breast, increasing resolution, and the images can be compared with the mammographic images. Breast-Specific Gamma Imaging and Molecular Breast Imaging differ primarily in the type and number of detectors used (multi-crystal arrays of cesium iodide or sodium iodide versus semiconductor materials, such as cadmium zinc telluride, respectively). In some configurations, a detector is placed on each side of the breast and used to lightly compress it. The maximum distance between the detector and the breast is therefore from the surface to the midpoint of the breast. Much of the research on BSGI and MBI has been conducted at the Mayo Clinic. The radiotracer usually utilized is technetium Tc99m sestamibi. MBI imaging takes approximately 40 minutes.

Preoperative lymphoscintigraphy and/or intraoperative hand-held gamma detection of sentinel lymph nodes is a method of identifying sentinel lymph nodes for biopsy after radiotracer injection. Surgical removal of 1 or more sentinel lymph nodes is an alternative to full axillary lymph node dissection for staging evaluation and management of breast cancer. Several trials have compared outcomes following sentinel lymph node biopsy versus axillary lymph node dissection for managing patients with breast cancer.

For individuals who have indeterminate or suspicious breast lesions who receive scintimammography, BSGI, or MBI, the evidence includes diagnostic accuracy studies. Relevant outcomes are overall survival, Scintimammography and Gamma Imaging of the Breast and Axilla disease-specific survival, test validity, and treatment-related morbidity. In the available studies, compared with biopsy, the negative predictive value of BSGI (or MBI) varied from 83% to 94%. Given the relative ease and diagnostic accuracy of the criterion standard of biopsy, coupled with the adverse consequences of missing a breast cancer, the negative predictive value of BSGI (or MBI) would have to be extremely high to alter treatment decisions. The evidence to date does not demonstrate this level of negative predictive value. Moreover, the value of BSGI in evaluating indeterminate or suspicious lesions must be compared with other modalities that would be used, such as spot views for diagnostic mammography. The evidence is insufficient to determine the effects of the technology on health outcomes.

## **CODING**

### **Medicare Advantage Plans and Commercial Products**

The following CPT code(s) is considered not covered for Medicare Advantage Plans and not medically necessary for Commercial Products as an adjunct to mammography or in staging the axillary lymph nodes:

**S8080** Scintimammography (radioimmunosintigraphy of the breast), unilateral, including supply of radiopharmaceutical

## **RELATED POLICIES**

High-Tech Radiology  
Radiopharmaceuticals

## **PUBLISHED**

Provider Update, October 2023  
Provider Update, February 2023  
Provider Update, January 2023  
Provider Update, January 2022  
Provider Update, January 2021

## **REFERENCES**

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Special report: screening symptomatic women with dense breasts and normal mammograms for breast cancer. TEC Assessments. 2013;Volume 28:Tab 15.

2. O'Connor M, Rhodes D, Hruska C. Molecular breast imaging. *Expert Rev Anticancer Ther.* Aug 2009; 9(8): 1073-80. PMID19671027
3. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-nodedissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. *Lancet Oncol.* Oct 2010; 11(10): 927-33. PMID 20863759
4. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. *J Surg Oncol.* Aug 01 2010; 102(2): 111-8. PMID 20648579
5. Ram R, Singh J, McCaig E. Sentinel Node Biopsy Alone versus Completion Axillary Node Dissection in Node Positive Breast Cancer: Systematic Review and Meta-Analysis. *Int J Breast Cancer.* 2014; 2014: 513780. PMID 25383226
6. DailyMed. Kit for the preparation of technetium Tc99m sestamibi. 2019; <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8c03a854-185a-45d7-883f-9f87e4750181>. Accessed August 25, 2022.
7. Hruska CB, O'Connor MK. Nuclear imaging of the breast: translating achievements in instrumentation into clinical use. *MedPhys.* May 2013; 40(5): 050901. PMID 23635248
8. Schillaci O, Spanu A, Danieli R, et al. Molecular breast imaging with gamma emitters. *Q J Nucl Med Mol Imaging.* Dec 2013; 57(4): 340-51. PMID 24322791
9. GE Healthcare. Myoview (Kit for the preparation of technetium Tc99m tetrofosmin for injection). 2017 April; <https://www.gehealthcare.com/-/jssmedia/918cbfdcae184f449d731d4dcffc492f.pdf?la=en-us>. August 25, 2022.
10. Aarsvold JN, Alazraki NP. Update on detection of sentinel lymph nodes in patients with breast cancer. *Semin Nucl Med.* Apr 2005; 35(2): 116-28. PMID 15765374
11. American College of Radiology (ACR). Appropriateness criteria: breast cancer screening. 2017; <https://acsearch.acr.org/docs/70910/Narrative/>. Accessed August 24, 2022.
12. Hruska CB, O'Connor MK. Curies, and Grays, and Sieverts, Oh My: A Guide for Discussing Radiation Dose and Risk of Molecular Breast Imaging. *J Am Coll Radiol.* Oct 2015; 12(10): 1103-5. PMID 26435124
13. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. *Radiology.* Oct 2010; 257(1): 246-53. PMID 20736332
14. Health risks from exposure to low levels of ionizing radiation: BEIR VII, Phase 2. Washington, DC: National Research Council of the National Academies Press; 2006.
15. Berrington de Gonzalez A, Berg CD, Visvanathan K, et al. Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. *J Natl Cancer Inst.* Feb 04 2009; 101(3): 205-9. PMID 19176458
16. Ernestos B, Nikolaos P, Koulis G, et al. Increased chromosomal radiosensitivity in women carrying BRCA1/BRCA2 mutations assessed with the G2 assay. *Int J Radiat Oncol Biol Phys.* Mar 15 2010; 76(4): 1199-205. PMID 20206018
17. Food and Drug Administration (FDA). 510(k) Summary: Gamma Medica™ Instruments: LumaGEM Scintillation Camera (K993813). 2000; [https://www.accessdata.fda.gov/cdrh\\_docs/pdf/K993813.pdf](https://www.accessdata.fda.gov/cdrh_docs/pdf/K993813.pdf). Accessed August 25, 2022.
18. BlueCross BlueShield Association. Breast-specific gamma imaging (BSGI), molecular breast imaging (MBI), or scintimammography with breast-specific gamma camera. *Technol Eval Cent Assess Program Exec Summ.* Jun 2013; 28(2): 1-4. PMID 23865107
19. Rhodes DJ, Hruska CB, Connors AL, et al. Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. *AJR Am J Roentgenol.* Feb 2015; 204(2): 241-51. PMID 25615744
20. Shermis RB, Wilson KD, Doyle MT, et al. Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue. *AJR Am J Roentgenol.* Aug 2016; 207(2): 450-7. PMID 27186635
21. Brem RF, Ruda RC, Yang JL, et al. Breast-Specific -Imaging for the Detection of Mammographically Occult Breast Cancer in Women at Increased Risk. *J Nucl Med.* May 2016; 57(5): 678-84. PMID 26823569

22. Zhang Z, Wang W, Wang X, et al. Breast-specific gamma imaging or ultrasonography as adjunct imaging diagnostics in women with mammographically dense breasts. *Eur Radiol.* Nov 2020; 30(11): 6062-6071. PMID 32524221
23. Rhodes DJ, Hruska CB, Phillips SW, et al. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. *Radiology.* Jan 2011; 258(1): 106-18. PMID 21045179
24. Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gammacamera in women at high risk for breast cancer. *Radiology.* Oct 2005; 237(1): 274-80. PMID 16126919
25. Cho MJ, Yang JH, Yu YB, et al. Validity of breast-specific gamma imaging for Breast Imaging Reporting and Data System 4 lesions on mammography and/or ultrasound. *Ann Surg Treat Res.* Apr 2016; 90(4): 194-200. PMID 27073789
26. Meissnitzer T, Seymer A, Keinrath P, et al. Added value of semi-quantitative breast-specific gamma imaging in the work-up of suspicious breast lesions compared to mammography, ultrasound and 3-T MRI. *Br J Radiol.* Jul 2015; 88(1051): 20150147. PMID 25882690
27. Tan H, Jiang L, Gu Y, et al. Visual and semi-quantitative analyses of dual-phase breast-specific gamma imaging with Tc-99m-sestamibi in detecting primary breast cancer. *Ann Nucl Med.* Jan 2014; 28(1): 17-24. PMID 24142630
28. Spanu A, Sanna D, Chessa F, et al. The clinical impact of breast scintigraphy acquired with a breast specific -camera (BSGC) in the diagnosis of breast cancer: incremental value versus mammography. *Int J Oncol.* Aug 2012; 41(2): 483-9. PMID 22641247
29. Hruska CB, Phillips SW, Whaley DH, et al. Molecular breast imaging: use of a dual-head dedicated gamma camera to detect small breast tumors. *AJR Am J Roentgenol.* Dec 2008; 191(6): 1805-15. PMID 19020253
30. Spanu A, Chessa F, Meloni GB, et al. The role of planar scintimammography with high-resolution dedicated breast camera in the diagnosis of primary breast cancer. *Clin Nucl Med.* Nov 2008; 33(11): 739-42. PMID 18936602
31. Brem RF, Petrovitch I, Rapelyea JA, et al. Breast-specific gamma imaging with 99mTc-Sestamibi and magnetic resonance imaging in the diagnosis of breast cancer--a comparative study. *Breast J.* Sep-Oct 2007; 13(5): 465-9. PMID 17760667
32. Guo C, Zhang C, Liu J, et al. Is Tc-99m sestamibi scintimammography useful in the prediction of neoadjuvant chemotherapy responses in breast cancer? A systematic review and meta-analysis. *Nucl Med Commun.* Jul 2016; 37(7): 675-88. PMID 26974314
33. Lee HS, Ko BS, Ahn SH, et al. Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients. *Breast Cancer Res Treat.* May 2014; 145(1): 91-100. PMID 24671359
34. Edwards C, Williams S, McSwain AP, et al. Breast-specific gamma imaging influences surgical management in patients with breast cancer. *Breast J.* Sep-Oct 2013; 19(5): 512-9. PMID 23848225
35. Xu HB, Li L, Xu Q. Tc-99m sestamibi scintimammography for the diagnosis of breast cancer: meta-analysis and meta-regression. *Nucl Med Commun.* Nov 2011; 32(11): 980-8. PMID 21956488
36. Taillefer R. The role of 99mTc-sestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis. *Semin Nucl Med.* Jan 1999; 29(1): 16-40. PMID 9990681
37. Schillaci O, Scopinaro F, Spanu A, et al. Detection of axillary lymph node metastases in breast cancer with Tc-99m tetrofosmin scintigraphy. *Int J Oncol.* Mar 2002; 20(3): 483-7. PMID 11836558
38. Spanu A, Dettori G, Nuvoli S, et al. (99mTc-tetrofosmin SPET in the detection of both primary breast cancer and axillary lymph node metastasis. *Eur J Nucl Med.* Dec 2001; 28(12): 1781-94. PMID 11734916
39. Pesek S, Ashikaga T, Krag LE, et al. The false-negative rate of sentinel node biopsy in patients with breast cancer: a meta-analysis. *World J Surg.* Sep 2012; 36(9): 2239-51. PMID 22569745
40. Thongvitokomarn S, Polchai N. Indocyanine Green Fluorescence Versus Blue Dye or Radioisotope Regarding Detection Rate of Sentinel Lymph Node Biopsy and Nodes Removed in Breast Cancer: A Systematic Review and Meta-Analysis. *Asian Pac J Cancer Prev.* May 01 2020; 21(5): 1187-1195. PMID 32458621

41. Goonawardena J, Yong C, Law M. Use of indocyanine green fluorescence compared to radioisotope for sentinel lymph node biopsy in early-stage breast cancer: systematic review and meta-analysis. *Am J Surg*. Sep 2020; 220(3): 665-676. PMID32115177
42. van der Vorst JR, Schaafsma BE, Verbeek FP, et al. Randomized comparison of near-infrared fluorescence imaging using indocyanine green and 99(m) technetium with or without patent blue for the sentinel lymph node procedure in breast cancer patients. *Ann Surg Oncol*. Dec 2012; 19(13): 4104-11. PMID 22752379
43. Johnson CB, Boneti C, Korourian S, et al. Intraoperative injection of subareolar or dermal radioisotope results in predictable identification of sentinel lymph nodes in breast cancer. *Ann Surg*. Oct 2011; 254(4): 612-8. PMID 21918427
44. Martin RC, Edwards MJ, Wong SL, et al. Practical guidelines for optimal gamma probe detection of sentinel lymph nodes in breast cancer: results of a multi-institutional study. For the University of Louisville Breast Cancer Study Group. *Surgery*. Aug 2000; 128(2): 139-44. PMID 10922983
45. Unkart J, Wallace A. Use of lymphoscintigraphy with Tc-99m tilmanocept does not affect the number of nodes removed during sentinel node biopsy in breast cancer [abstract]. *J Nucl Med*. 2016;57(Suppl 2):615.
46. Sun X, Liu JJ, Wang YS, et al. Roles of preoperative lymphoscintigraphy for sentinel lymph node biopsy in breast cancer patients. *Jpn J Clin Oncol*. Aug 2010; 40(8): 722-5. PMID 20430775
47. Mathew MA, Saha AK, Saleem T, et al. Pre-operative lymphoscintigraphy before sentinel lymph node biopsy for breast cancer. *Breast*. Feb 2010; 19(1): 28-32. PMID 19913418
48. Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. *Obstet Gynecol*. Jul 2017; 130(1): e1-e16. PMID 28644335
49. American College of Radiology (ACR). Appropriateness criteria: palpable breast masses. 2016; <https://acsearch.acr.org/docs/69495/Narrative/>. Accessed August 22, 2022.
50. American College of Radiology (ACR). Appropriateness criteria: breast pain. 2018; <https://acsearch.acr.org/docs/3091546/Narrative/>. Accessed August 23, 2022.
51. Monticciolo DL, Newell MS, Moy L, et al. Breast Cancer Screening in Women at Higher-Than-Average Risk: Recommendations From the ACR. *J Am Coll Radiol*. Mar 2018; 15(3 Pt A): 408-414. PMID 29371086
52. American College of Radiology (ACR). Appropriateness criteria: Supplemental breast cancer screening based on breast density. 2021; <https://acsearch.acr.org/docs/70910/Narrative/>. Accessed August 25, 2022.
53. Lyman GH, Somerfield MR, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: 2016 American Society of Clinical Oncology Clinical Practice Guideline Update Summary. *J Oncol Pract*. Mar 2017; 13(3): 196-198. PMID 28118104
54. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 4.2022. [https://www.nccn.org/professionals/physician\\_gls/pdf/breast.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf). Accessed August 24, 2022.
55. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Screening and Diagnosis. Version 1.2022. 2022; [https://www.nccn.org/professionals/physician\\_gls/pdf/breast-screening.pdf](https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf). Accessed August 25, 2022.

**CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS**

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

